IGF2BP1 and neuroendocrine neoplasm: demonstrated that BTYNB suppresses the IGF2BP1/MYC/EZH2 axis’s pro-proliferative effects on neuroendocrine neoplasms by blocking IGF2BP1 binding to MYC mRNA (203).